European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI …

| April 6, 2015 | 0 Comments

THOUSAND OAKS, Calif., April 6, 2015 /PRNewswire/ — Amgen (AMGN) today announced that the European Commission approved a new use of Vectibix® (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). About half of the patients with mCRC have WT RAS tumors.1  FOLFIRI, an irinotecan-based …

See more here:
European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI …

Tags: , , , , , , , , , , ,

Category: Recent News

About the Author ()

Leave a Reply